Niraparib treatment had no effect on the growth of the three BRCAWT, ATMWT NSCLC PDX models that contained a biallelic deleterious mutation in either RAD51B, RAD51D, or XRCC2 (0%–20% TGI, Figure 5A). Here, RAD51B is linked to non-small cell lung carcinoma.